Johnson And Johnson To Split Into Two Separate Companies

(Photo by MARK RALSTON/AFP via Getty Images)

Daily Caller News Foundation logo
Harry Wilmerding Contributor
Font Size:

Johnson and Johnson (J&J) announced Friday that it plans to break up its two companies, separating its consumer health business into its own publicly-traded company.

The health care giant said it would separate the division that sells consumer products like Band-Aids, Listerine and Tylenol from its riskier and faster-growing pharmaceutical and medical device business, according to a company press release. The consumer division, which generates $15 billion in revenue a year, will operate independently in the next 18 to 24 months. (RELATED: Johnson & Johnson Reports Nine-Fold Increase Of Antibodies After Booster)

“Following a comprehensive review, the Board and management team believe that the planned separation of the Consumer Health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and – most importantly – improve healthcare outcomes for people around the world,” chief executive Alex Gorsky said in the press release.

The segment selling prescription drugs and medical devices will keep the J&J name while the consumer health company has not yet been named, according to the press release. Consumer health has four brands that generate over $1 billion in annual sales and another 20 bringing in over $150 million.

By separating into two companies, the consumer brand will have the ability to be more agile, adapting to trends within the market and allowing for better allocation of capital, Gorsky said.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact